Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma‐associated antigen‐A3 expression through Yes‐associated protein inactivation

Abstract

Sitagliptin is an emerging oral hypoglycemic agent that inhibits the development of a wide variety of tumors. Current researches indicate that the abnormal activation of Yes-associated protein (YAP) promotes the proliferation and poor prognosis of multiple tumors. However, the ability of sitagliptin to regulate YAP and its effects on gastric cancer (GC) cells remain unclear. Here, we first showed that sitagliptin inhibited the proliferation of GC cells, and this inhibition was regulated by Hippo pathway. Sitagliptin phosphorylated YAP in a large tumor suppressor homolog-dependent manner, thereby inhibiting YAP nuclear translocation, and promoted YAP cytoplasm retention. This inhibition can be blocked by adenosine 5′-monophosphate-activated protein kinase (AMPK). Moreover, sitagliptin could reduce the expression of tumor-testis antigen Melanoma-associated antigen-A3 through YAP. In conclusion, sitagliptin may have a potential inhibitory effect on GC by AMPK/YAP/ melanoma-associated antigen-A3 pathway. K E Y W O R D Sgastric cancer, MAGE-A3, sitagliptin, YAP

Dihydroartemisinin suppresses proliferation, migration, the Wnt/β‑catenin pathway and EMT via TNKS in gastric cancer

“…The occurrence of gastric cancer is an intricate process, involving the abnormal expression of several genes ( 8 , 9 ). Tankyrases (TNKS), as member of the poly (ADP-ribose) polymerase (PARP) family, has two subtypes, TNKS1 and TNKS2 ( 10 ).…”

Pathway-Based Drug Repurposing with DPNetinfer: A Method to Predict Drug–Pathway Associations via Network-Based Approaches

“…40,41 Sitagliptin would affect gastric cancer cells proliferation by suppressing melanomaassociated antigen-A3 expression. 42 In another network-based drug repurposing approach we developed for prediction of ATC codes, 24 a very good consistency (62% coverage with L ≤ 3) was obtained with this DPNetinfer method (Table S8). Therefore, DPNetinfer would provide a new way to drug repurposing.…”

Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents

“…A repositioning study showed that linagliptin had a therapeutic effect on colorectal cancer based on molecular docking and gene expression profiling methods, and this result was verified by in vivo experiments [122] . Another cell study showed that sitagliptin had a potential inhibitory effect on proliferation and clonality of gastric cancer cells by activating AMPK and inhibiting Yes‐associated protein (YAP) and Melanoma‐associated antigen‐A3 (MAGE‐A3) [123] . Besides, sitagliptin was also associated with a reduced risk of colorectal cancer [124] , [125] .…”